Rosuline

📦 Jokainen tilaus on katettuna meidän Reshipment Assurance Policy -politiikkamme piiriin — jos lähetyksesi ei saavu 20 arkipäivässä, lähetämme uuden.

Miksi tilata MedsBasesta

Geneeriset lääkkeemme on hankittu WHO-GMP sertifioiduilta valmistajilta ja toimitettu maailmanlaajuisesti hienotunteisessa, neutraalissa pakkauksessa — lääkkeen nimeä ei ole pakkauksen ulkopuolella. Korttimaksut käsitellään säädeltyjen maksunvälittäjien kautta (tilisiirtojen kuvaukset sisältävät säädellyn korttimaksun käsittelijän — ei koskaan “MedsBase” tai lääkkeen nimeä). Kryptovaluutat ja SEPA-pankkisiirrot hyväksytään myös. Jokainen tilaus on turvattu meidän Reshipment Assurance Policy -takuuohjelmalla.

What Is Rosuline?

Rosuline is an oral 5 / 10 mg rosuvastatin tablet from Torrent Pharma, supplied in 30-180 tablets. Rosuvastatin was introduced by AstraZeneca in 2003 as Crestor. Hydrophilic statin; primarily excreted unchanged in faeces (10% renal, 90% biliary); minimal CYP metabolism (mostly CYP2C9 modestly). Dose range 5-40 mg once daily; 20-40 mg are high-intensity.

How Rosuvastatin Works

Rosuvastatin inhibits HMG-CoA-reduktaasille, the rate-limiting enzyme of hepatic cholesterol biosynthesis. Downstream:

• Reduced intracellular cholesterol in hepatocytes — triggers sterol-regulatory element binding protein (SREBP) activation and upregulation of LDL-receptor expression on the hepatocyte surface
• Increased clearance of circulating LDL-C — the primary LDL-lowering mechanism
• Modest triglyceride reduction (10-20%) and modest HDL rise (5-10%)
• Pleiotropic effects beyond LDL-lowering — reduced vascular inflammation (hs-CRP drop), improved endothelial function, plaque stabilisation, reduced platelet reactivity. The magnitude of the clinical benefit across trials exceeds what is explained by LDL-C change alone.

Rosuline Dosage

Primary prevention (no prior CV event): start 5-10 mg once daily; titrate to target based on 10-year ASCVD risk. For diabetics or ASCVD risk >7.5%, moderate-intensity (10-20 mg) is typical.

Secondary prevention (prior MI, stroke, PAD, or diabetic CVD): high-intensity therapy — 20-40 mg once daily. Target LDL-C <1.8 mmol/L (<70 mg/dL) per 2019 ESC and <1.4 mmol/L (<55 mg/dL) for very-high-risk ASCVD per 2021 ESC update.

Familial hypercholesterolaemia: maximum-tolerated statin (usually 40 mg) often combined with ezetimibe 10 mg and/or PCSK9 inhibitor (alirocumab/evolocumab/inclisiran) to achieve guideline targets.

Annostelu: once daily with or without food. Any time of day — 19-hour half-life means timing does not meaningfully change efficacy.

Seuranta:

• Alkutilanne: full lipid panel, LFTs (ALT), creatine kinase (CK), HbA1c or fasting glucose, creatinine, thyroid-stimulating hormone (TSH) if not recently checked.
• 4-12 viikkoa: repeat lipids to assess response. Expect rosuvastatin 20 mg reduces LDL-C by 52%; 40 mg by 55% — the most potent statin per mg. Dose-escalate if target not met.
• Vuosittain: lipids, LFTs (unless symptomatic). CK only on muscle complaints, not routinely.
• Keskeytä ja tutki: CK >10× ULN, ALT >3× ULN and rising, persistent unexplained muscle pain with CK >5× ULN, rhabdomyolysis (dark urine, profound weakness).

Evidence for Rosuvastatin

JUPITER (2008) — rosuvastatin 20 mg in 17,802 patients with normal LDL but elevated hs-CRP reduced CV events by 44%; extended statin indications to “inflammation-driven” risk. ASTEROID (2006) — 40 mg for 24 months produced measurable coronary plaque regression on IVUS. SATURN (2011) — rosuvastatin 40 mg vs atorvastatin 80 mg; rosuvastatin slightly greater LDL reduction but no meaningful regression advantage. HOPE-3 (2016) — rosuvastatin 10 mg primary prevention in intermediate-risk patients reduced CV events by 24%.

Hyväksytyt ja tutkimusnäyttöön perustuvat käyttöalueet

• Primary and secondary prevention of cardiovascular disease
• Inflammation-driven risk with elevated hs-CRP (JUPITER)
• Patients who are CYP3A4-interaction-prone (simpler pharmacology than atorvastatin)
• Perinnöllinen hyperkolesterolemia

Practical Considerations

Fewer CYP3A4 interactions than atorvastatin — a practical advantage when patients take macrolides, azoles, or certain antiretrovirals. Dose-capped in Asian patients — the FDA reduced the Asian starting dose to 5 mg after pharmacokinetic studies showed 2-fold higher plasma levels. Creatine kinase and LFT monitoring as for all statins.

Haittavaikutukset

Yleiset (>1%):

• Myalgia (muscle pain) — bothersome in 5-10% of users; confirmed statin-associated muscle symptoms with CK rise in 0.1-1%. High nocebo component: SAMSON trial (2020) showed no difference between statin and placebo in double-blind n-of-1 crossovers in many “statin-intolerant” patients.
• Lieviä transaminaasien nousuja — 3% have ALT rise below 3× ULN; usually transient and does not require dose change.
• New-onset diabetes — absolute excess ~0.2 per 100 patient-years, mostly in prediabetic patients. CV benefit far exceeds diabetes risk.
• Headache, dyspepsia, nausea
• Erektiohäiriö (uncommon; mechanism unclear)
• Sleep disturbance, cognitive fog (reported but not consistent in RCTs)

Epätyypillisiä mutta kliinisesti merkittäviä:

• Rhabdomyolyysi (<1 per 10,000 patient-years) — severe muscle breakdown, renal failure risk. Stop immediately on dark urine + profound weakness + CK >10× ULN.
• Immuunivälitteinen nekrotoiva myopatia — rare persistent myopathy that continues after stopping statin; anti-HMGCR antibody mediated. Needs immunosuppressive treatment.
• Severe transaminitis / drug-induced liver injury — rare; stop if ALT >3× ULN with symptoms or rising trajectory.
• Perifeerinen neuropatia (harvinainen)

Käyttökiellot

• Raskaus ja imetys — statins are contraindicated; cholesterol is required for fetal neurodevelopment.
• Aktiivinen maksasairaus or unexplained persistent ALT >3× ULN.
• Prior rhabdomyolysis or severe statin-intolerance confirmed in double-blind rechallenge.
• Samanaikaiset voimakkaat CYP3A4-estäjät (for rosuvastatin): clarithromycin, itraconazole, ritonavir — hold statin or switch to rosuvastatin/pravastatin.
• Hypersensitivity to the statin.

Lääkeaineenvaihdunta

• CYP2C9 and OATP1B1 transporter interactions — ciclosporin, gemfibrozil, and some antiretrovirals raise rosuvastatin levels. Dose-cap rosuvastatin at 5 mg with ciclosporin; avoid with gemfibrozil.
• Greippimehu — minimal interaction with rosuvastatin (hydrophilic; minimal CYP3A4 metabolism).
• Fibrates (gemfibrozil, fenofibrate) — additive myopathy risk. Gemfibrozil is the worst; fenofibrate is the preferred fibrate for combination. Reserve combinations for specialist dyslipidaemia care.
• Niacin high-dose — additive myopathy risk. Low-dose niacin (1-2 g) usually tolerated.
• Varfariini — small INR rise with statin initiation; check INR 1 week after starting. Not a contraindication.
• Digoksiini — small digoxin level rise with atorvastatin (P-glycoprotein); usually not clinically significant.
• Alkoholi — heavy intake raises liver injury risk. Moderate intake is acceptable.

Säilytys

Store Rosuline below 25°C in the original blister pack. Keep out of reach of children.

Usein Kysytyt Kysymykset

Do I have to take Rosuline at night?

No — rosuvastatin has a 19-hour half-life, long enough that the ~24-hour cycle of nocturnal cholesterol synthesis is covered regardless of dose timing. Morning dosing with other medications is fine. The “take statins at night” rule comes from short-half-life statins (simvastatin, lovastatin).

What if I get muscle aches on Rosuline?

Common and rarely dangerous. Check creatine kinase (CK). If CK is normal, the pains are usually not statin-related — the SAMSON trial (2020) showed most “statin-intolerant” patients had equal aches on placebo in double-blind crossover. Options: continue statin with vitamin D supplementation (if deficient), try coenzyme Q10 (weak evidence but low-risk), switch statin (rosuvastatin has lower muscle-symptom rate than simvastatin and atorvastatin in some trials), lower the dose, or adopt alternate-day dosing. Only stop if CK >10× ULN, symptoms are disabling, or there is objective weakness.

Will Rosuline give me diabetes?

Statins cause a small excess of new-onset diabetes — approximately 1 extra diabetes case per 1,000 people per year, mostly in those already at high diabetes risk (overweight, prediabetes, family history). The same treatment prevents roughly 5-10 cardiovascular events per 1,000 people per year in the same populations — so the net benefit is strongly positive. Do not stop a statin because of diabetes risk alone.

Can I take Rosuline with grapefruit juice?

Yes — rosuvastatin has minimal CYP3A4 metabolism, so the grapefruit interaction is minor. Contrast with atorvastatin where regular grapefruit consumption is discouraged.

How long will I need to take Rosuline?

Indefinitely, in almost all cases. Stopping a statin causes LDL-C to rebound within weeks and cardiovascular protection is lost within months. Statins are lifelong preventive therapy for atherosclerotic disease, not a short course.

Can I take Rosuline in pregnancy?

No — statins are contraindicated in pregnancy and breastfeeding. Cholesterol is required for fetal neurodevelopment; statins cross the placenta. Stop the statin before planned pregnancy; if pregnancy is unplanned, stop immediately and discuss risks with a specialist. Familial hypercholesterolaemia patients can usually safely defer statin therapy during pregnancy and breastfeeding.

Where can I buy Rosuline online?

You can buy Rosuline (rosuvastatin 5 / 10 mg, 30-180 tablets) from MedsBase with discreet packaging and worldwide shipping.

Aiheeseen liittyvät sydän- ja verenpainelääkkeet

• Aldactone — Spironolactone (ei-selektiivinen MR-antagonisti)
• Amlopres AT — Amlodipine + Atenolol -yhdistelmä
• Aten — Atenolol (beta-salpaaja)
• Ecosprin — Aspiriini 75/150 mg
• Eptus — Eplerenoni 25/50 mg (selektiivinen MR-antagonisti)
• Lotensyl — Cilnidipine 10/20 mg (L+N-tyyppinen kalsiumkanavan estäjä)
• Selaa kaikkia verenpainelääkkeitä

Miksi tilata MedsBasesta

Rosuline is supplied through a WHO-GMP certified manufacturer with full COA documentation. We ship worldwide in plain, discreet packaging, and every order is covered by our Reshipment Assurance Policy -politiikkamme piiriin. Korttimaksun tiliotteesi näyttää säännellyn maksunvälittäjän (säännelty korttimaksujen käsittelijä), ei koskaan “MedsBase” tai minkään lääkkeen nimeä.

Aiheeseen liittyvät vaihtoehdot

Muut tuotteet Krooniset sairaudet joita asiakkaat myös katsovat:

• Triohale-inhaloija
• Montair
• Lomoother
• Unicontin-E
• Ventocortil

Lisää vaihtoehtoja korkean kolesterolitason hoidoissa

Luokiteltu MedsBase-tilausmäärän mukaan — mitä muut asiakkaat tässä kategoriassa valitsevat.

Ezedoc

US$36.00 – US$124.00Interval de preț: US$36.00 până la US$124.00

Lipvas

US$12.00 – US$117.00Interval de preț: US$12.00 până la US$117.00

Choltran Sachet

US$24.00 – US$94.00Interval de preț: US$24.00 până la US$94.00

Lipicard

US$34.00 – US$175.00Interval de preț: US$34.00 până la US$175.00